The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Moffitt researchers discover pathways to activate dendritic cells, produce strong anti-tumor immunity

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

In a study published in Cancer Immunology Research, researchers at Moffitt Cancer Center, led by Amer A. Beg, show how stimulating dendritic cells through the CD40 and interferon β pathways produces strong T-cell activity against tumors and works in conjunction with immune checkpoint inhibitors to produce even stronger responses. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Ruxolitinib improves CML’s response to standard TKI treatment

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib (Jakafi) to standard tyrosine kinase inhibitor treatment for patients with chronic-phase chronic myeloid leukemia significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment. Results were presented at the European School of Haematology’s 26th Annual John...

In Brief

Greg Sawyer receives Tribology Gold Medal

Greg Sawyer, chair of the bioengineering department at Moffitt Cancer Center, has been awarded the 2023 Tribology Gold Medal by the International Tribology Council. This prestigious award is the highest honor in the field and recognizes individuals who have made extraordinary lifetime contributions to the study of friction, wear, and lubrication.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account